2/5
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2/2
08:05 am
mdgl
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Low
Report
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
1/29
07:41 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
06:00 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/22
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
1/21
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
1/20
09:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $527.00 to $745.00. They now have a "market outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $527.00 to $745.00. They now have a "market outperform" rating on the stock.
1/20
07:01 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
1/14
07:36 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/14
03:01 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/12
09:08 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/10
01:24 pm
mdgl
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
Low
Report
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
1/10
03:36 am
mdgl
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
1/9
08:00 am
mdgl
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Medium
Report
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
1/6
07:28 pm
mdgl
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
Low
Report
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
1/6
09:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $579.00 price target on by analysts at Wolfe Research.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $579.00 price target on by analysts at Wolfe Research.
1/6
08:06 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
1/5
05:23 pm
mdgl
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead [Yahoo! Finance]
Medium
Report
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead [Yahoo! Finance]
1/5
11:22 am
mdgl
$18.67 Bn MASH Treatment Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029 & 2034 [Yahoo! Finance]
Low
Report
$18.67 Bn MASH Treatment Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029 & 2034 [Yahoo! Finance]
1/5
08:44 am
mdgl
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data [Seeking Alpha]
Low
Report
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data [Seeking Alpha]
1/3
04:25 am
mdgl
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade [Seeking Alpha]
Low
Report
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade [Seeking Alpha]
12/23
01:28 pm
mdgl
Here are the most and least likely M&A targets in biotech, according to Truist [Seeking Alpha]
Low
Report
Here are the most and least likely M&A targets in biotech, according to Truist [Seeking Alpha]
12/19
02:28 pm
mdgl
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1-Year Share Price Surge [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1-Year Share Price Surge [Yahoo! Finance]
12/19
08:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $900.00 price target on by analysts at UBS Group AG.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $900.00 price target on by analysts at UBS Group AG.
12/19
07:19 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "overweight" rating reaffirmed by analysts at Piper Sandler.